Catalyst Pharmaceutical: A Top Value Stock for Long-Term Investors
ByAinvest
Friday, Jul 4, 2025 11:07 am ET1min read
CPRX--
Catalyst Pharmaceutical (CPRX) is a top value stock for the long-term, according to Zacks Investment Research. With a Zacks Rank #2 (Buy) and a Value Style Score of A, CPRX is trading at a forward P/E of 9.6X, compared to the Medical - Drugs industry's P/E of 13.1X. The company has a PEG Ratio of 0.8, a Price/Cash Flow ratio of 8.8X, and a Price/Sales ratio of 4.9X. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025, with an average earnings surprise of 28.2%. CPRX is a strong value and VGM stock with impressive earnings and valuation fundamentals.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet